Advertisement

Topics

Search Results for "Mirrx Therapeutics"

12:42 EDT 27th July 2017 | BioPortfolio

Matching Channels

Tuberculosis Vaccines and Therapeutics

The WHO estimates that the largest number of new tuberculosis (TB) cases in 2008 occurred in the South-East Asia Region, which accounted for 34% of incident cases globally. However, the estimated inci...

KIACTA

KIACTA™ (also known as eprodisate) is an orally bioavailable small molecule intended for the treatment of AA amyloidosis, an orphan indication that results from long-standing inflammatory cond...

Anthrax Vaccines and Therapeutics

Anthrax is a zoonotic disease caused by the spore-forming bacterium Bacillus anthracis. The disease most commonly occurs in mammals (e.g., cattle, sheep, goats, camels, antelope. Anthrax occurs in hu...

AUT00063

AUT00063 develpoed by Autifony Therapeutics, is a novel, orally active small molecule designed to selectively modulate Kv3 potassium channels, which are important in central auditory processing. Pre...

Facebook - BioPortfolio Pages

BioPortfolio has launched a number of Facebook pages to allow our visitors to keep track with latest news, published paper and clinical trials by lead biotechnology and healthcare topics:- &nbs...

Matching News

Summit Therapeutics PLC (SMMT) and Orexigen Therapeutics (OREX) Head to Head Review

Summit Therapeutics PLC and Orexigen Therapeutics are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, in...

CRISPR Therapeutics, Casebia Therapeutics partner with StrideBio

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a joint-venture established by CRISPR Therapeut...

RaNA Therapeutics Relaunches as Translate Bio to Advance RNA Therapeutics

Tuesday, June 27th 2017 at 11:00am UTC — Company Expands Executive Leadership Team with Key Appointments in Early 2017 — CAMBRIDGE, Mass.–(BUSINESS WIRE)– RaNA Therapeutics tod...

CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration

CAMBRIDGE, Mass. and BASEL, Switzerland, July 10, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines...

M&As this week: Bioverativ Therapeutics, Horizon Pharma

Bioverativ Therapeutics has reached an agreement to acquire clinical-stage biotechnology company True North Therapeutics.

Dragonfly Therapeutics names world leader in NK therapeutics as CSO

Dragonfly Therapeutics has appointed Nicolai Wagtmann as its chief scientific officer (CSO).

Deals this week: Akcea Therapeutics, Atara Biotherapeutics, Numab Therapeutics

Akcea Therapeutics plans to raise up to $100m through an initial public offering of its common stock shares.

Deals this week: Spero Therapeutics, BioCryst Pharmaceuticals, Breath Therapeutics Holding

Spero Therapeutics has announced it has raised $51.7m in a series C financing round led by GV (formerly Google Ventures).

Matching PubMed Articles

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement